Genprex, Inc.
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study will be conducted in 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Small Cell Lung Cancer Extensive Stage
quaratusugene ozeplasmid
atezolizumab
Phase 1
Phase 2
Acclaim-3 is an open-label, multi-center, Phase 1/2 study evaluating the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with ES-SCLC who did not develop tumor progression after receiving at least 3 cycles, and no more than 4 cycles, of induction therapy with carboplatin plus etoposide and atezolizumab. Toxicities will be assessed by the Investigator using United States National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Serious Adverse Events and Dose Limiting Toxicities (DLTs) will be reviewed by a safety review committee. Phase 1: In Phase 1 dose selection, patients will be enrolled in sequential cohorts treated with successively higher doses of quaratusugene ozeplasmid in combination with atezolizumab. The recommended Phase 2 dose (RP2D) of quaratusugene ozeplasmid when given in combination with atezolizumab will be identified. Phase 2: Quaratusugene ozeplasmid in combination with atezolizumab will be further evaluated using the RP2D identified in Phase 1.}}
Study Type : | Interventional |
Estimated Enrollment : | 62 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
Actual Study Start Date : | April 2024 |
Estimated Primary Completion Date : | February 2026 |
Estimated Study Completion Date : | August 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Phase 1 Up to 2 sequential dose selection cohorts will be treated with quaratusugene ozeplasmid (intravenous (IV) administration once every 21 days) plus atezolizumab (1200 mg IV administration once every 21 days) until disease progression or unacceptable toxicity. Quaratusugene ozeplasmid doses will be evaluated (0.09 [starting dose], and 0.12 mg/kg) until the RP2D is identified. |
Biological: quaratusugene ozeplasmid Biological: atezolizumab |
Experimental: Phase 2 Patients will be treated with the RP2D of quaratusugene ozeplasmid (IV administration once every 21 days) plus atezolizumab (1200 mg IV administration once every 21 days) until disease progression or unacceptable toxicity |
Biological: quaratusugene ozeplasmid Biological: atezolizumab |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Rocky Mountain Cancer Centers, LLP
Lone Tree, Colorado, United States, 80124
Recruiting
Washington University School of Medicine - Siteman Cancer Center
Saint Louis, missouri, United States, 63110
Recruiting
Willamette Valley Cancer Institute (Oregon)
Eugene, Oregon, United States, 97401
Recruiting
Northwest Cancer Specialists, P.C.
Portland, Oregon, United States, 97213-2982
Recruiting
Providence Cancer Institute
Portland, Oregon, United States, 97213
Recruiting
Northwest Cancer Specialists, P.C.
Portland, Oregon, United States, 97227
Recruiting
Northwest Cancer Specialists, P.C.
Tigard, Oregon, United States, 97223
Recruiting
Texas Oncology - DFW
dallas, Texas, United States, 75246
Recruiting
Texas Oncology - Northeast Texas
Tyler, Texas, United States, 75702
Recruiting
Northwest Cancer Specialists, P.C.
Vancouver, Washington, United States, 98684